RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases

Expert Opinion on Biological Therapy

Volumn 9, Issue 4, 2009, Pages 465-479

  Terpos, Evangelos ^a   Efstathiou, Eleni ^a   Christoulas, Dimitrios ^a   Roussou, Maria ^a   Katodritou, Eirini ^b   Dimopoulos, Meletios Athanassios ^a  

^a ALEXANDRA HOSPITAL   (Greece)

^b Theagenion Anticancer Institute   (Greece)

Author keywords

Bone disease; Bone metastases; Cancer; Denosumab; Multiple myeloma; Osteoprotegerin; RANKL

Indexed keywords

ADENOVIRUS VECTOR; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; DOCETAXEL; NOGGIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; PLACEBO; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANEMIA; ASTHENIA; BONE METASTASIS; BONE PAIN; BONE REMODELING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONSTIPATION; DOSAGE SCHEDULE COMPARISON; DRUG FATALITY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; HYPERCALCEMIA; INHIBITION KINETICS; JAW OSTEONECROSIS; KIDNEY FAILURE; LUNG CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOSARCOMA; PROSTATE CANCER; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; DISEASE MANAGEMENT; HUMANS; MULTIPLE MYELOMA; RANK LIGAND;

EID: 67649280600     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590902845610     Document Type: Review

References (101)

1. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12(20 Pt 2):6243s-9s (Pubitemid 44703797)
2. Lipton A, Cook RJ, Major P, et al. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007;12:1035-1043 (Pubitemid 350007015)
3. Loberg RD, Logothetis CJ, Keller ET, Pienta K. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol 2005;23:8232-8241 (Pubitemid 46211560)
4. Hirsh V, Major PP, Lipton A, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008;3:228-236 (Pubitemid 351654321)
5. Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol 2005;16:1223-1231 (Pubitemid 41158467)
6. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33 (Pubitemid 36033957)
7. Callander NS, Roodman GD. Myeloma bone disease. Semin Hematol 2001;38:276-285 (Pubitemid 32717665)
8. Cook R. Economic and clinical impact of multiple myeloma to managed care. J Manag Care Pharm 2008;14(7 Suppl):19-25
9. Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110:1860-1867 (Pubitemid 47557312)
10. Lipton A. Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs 2003;8:469-488 (Pubitemid 37522661)
11. Terpos E, Rahemtulla A. Bisphosphonate treatment for multiple myeloma. Drugs Today 2004;40:29-40 (Pubitemid 38270553)
12. Kyle RA, Yee GC, Somerfield MR, et al. American society of clinical oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2464-2472 • Guidelines for the management of myeloma bone disease with bisphosphonates form the American Society of Clinical Oncology (ASCO).
13. Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European myeloma network. Ann Oncol 2009 (In Press) • Guidelines for the management of myeloma bone disease with bisphosphonates form the European Myeloma Network (EMN).
14. Roodman GD. Advances in bone biology: the osteoclast. Endocr Rev 1996;17:308-332 •• A review on osteoclast differentiation and function. (Pubitemid 26277978)
15. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 2004;127:127-139 (Pubitemid 39371805)
16. Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev 2008;29:403-440 •• A review on the interactions between bone and immune cells.
17. Itoh K, Udagawa N, Matsuzaki K, et al. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. J Bone Miner Res 2000;15:1766-1775 (Pubitemid 30666230)
18. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323 •• The first paper, to our knowledge, on the role of RANKL in osteoclastogenesis & lymph-node organogenesis. (Pubitemid 29061638)
19. Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclear factor-κB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 2001;92:460-470 (Pubitemid 32735180)
20. Giuliani N, Colla S, Morandi F, Rizzoli V. The RANK/RANK ligand system is involved in intereleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment. Haematologica 2004;89:1118-1123 (Pubitemid 39295483)
21. Hofbauer LC, Lacey DL, Dunstan CR, et al. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999;25:255-259 (Pubitemid 29406050)
22. Han JH, Choi SJ, Kurihara N, et al. Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligand. Blood 2001;97:3349-3353
23. Duplomb L, Baud'huin M, Charrier C, et al. Interleukin-6 inhibits receptor activator of nuclear factor κB ligandinduced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3. Endocrinology 2008;149:3688-3697
24. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319 •• The first paper, to our knowledfe, on the role of osteoprotegerin in bone metabolism. (Pubitemid 27199902)
25. Li Y, Toraldo G, Li A, et al. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 2007;109:3839-3848 • A paper on the role of T- and B-cells in bone homeostasis. (Pubitemid 46641735)
26. Kim N, Odgren PR, Kim DK, et al. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci USA 2000;97:10905-10910 (Pubitemid 30751252)
27. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-1268 (Pubitemid 28213402)
28. Aubin JE. Regulation of osteoblast formation and function. Rev Endocr Metab Disord 2001;2:81-94 (Pubitemid 33643895)
29. Ducy P, Zhang R, Geoffroy V, et al. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997;89:747-754 (Pubitemid 27516177)
30. Bennett CN, Longo KA, Wright WS, et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 2005;102:3324-3329 (Pubitemid 40328044)
31. Noble BS. The osteocyte lineage. Arch Biochem Biophys 2008;473:106-111
32. Seeman E, Delmas PD. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006;354:2250-2261 • A review on bone quality and factors that influence bone strength and fragility. (Pubitemid 43788139)
33. van Bezooijen RL, Svensson JP, Eefting D, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 2007;22:19-28 (Pubitemid 46032593)
34. Zhao S, Zhang YK, Harris S, et al. MLO-Y4 osteocyte-like cells support osteoclast formation and activation. J Bone Miner Res 2002;17:2068-2079 (Pubitemid 35239208)
35. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-593 (Pubitemid 37328925)
36. Clarke NW, McClure J, George NJ. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991;68:74-80
37. Terpos E, Politou M, Rahemtulla A. New insights into the pathophysiology and management of bone disease in multiple myeloma. Br J Haematol 2003;123:758-769 (Pubitemid 37533288)
38. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001;98:11581-11586 • A basic paper on the role of RANKL/OPG disruption in myeloma bone disease. (Pubitemid 32928771)
39. Giuliani N, Colla S, Sala R, et al. Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 2002;100:4615-4621 (Pubitemid 35429706)
40. Roux S, Meignin V, Quillard J, et al. RANK (receptor activator of nuclear factor-κB) and RANKL expression in multiple myeloma. Br J Haematol 2002;117:86-92 (Pubitemid 34304425)
41. Giuliani N, Bataille R, Mancini C, et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001;98:3527-3533
42. Shaughnessy JD, Barlogie B. Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling. Immunol Rev 2003;194:140-163 (Pubitemid 36886434)
43. Heider U, Langelotz C, Jakob C, et al. Expression of receptor activator of nuclear factor κB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 2003;9:1436-1440 (Pubitemid 36418398)
44. Farrugia AN, Atkins GJ, To LB, et al. Receptor activator of nuclear factor-κB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 2003;63:5438-5445 (Pubitemid 37139862)
45. Lai FP, Cole-Sinclair M, Cheng WJ, et al. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br J Haematol 2004;126:192-201 (Pubitemid 38961937)
46. Giuliani N, Colla S, Morandi F, et al. Lack of receptor activator of nuclear factor-κB ligand (RANKL) expression and functional production by human multiple myeloma cells. Haematologica 2005;90:275-278 (Pubitemid 40293301)
47. Standal T, Seidel C, Hjertner O, et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002;100:3002-3007
48. Qiang YW, Chen Y, Stephens O, et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008;112:196-207 • A paper on the role of Dkk-1 in the regulation of RANKL and OPG in myeloma.
49. Seidel C, Hjertner Ø, Abildgaard N, et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001;98:2269-2271
50. Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) ratio predicts survival in multiple myeloma. Proposal for a novel prognostic index. Blood 2003;102:1064-1069 • A paper on the role of RANKL/OPG in myeloma patients' survival. (Pubitemid 36917805)
51. Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999;140:4451-4458 (Pubitemid 30666108)
52. Ohshiba T, Miyaura C, Inada M, Ito A. Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis. Br J Cancer 2003;88:1318-1326 (Pubitemid 36606352)
53. Inoue H, Nishimura K, Oka D, et al. Prostate cancer mediates osteoclastogenesis through two different pathways. Cancer Lett 2005;223:121-128 (Pubitemid 40693716)
54. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006;440:692-696 • A basic paper on the role of RANKL in cancer cell migration and bone metastases.
55. Nakamura ES, Koizumi K, Kobayashi M, et al. RANKL-induced CCL22/ macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4. Clin Exp Metastasis 2006;23:9-18 (Pubitemid 44576775)
56. Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001;57:611-616
57. Van Poznak C, Cross SS, Saggese M, et al. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours. J Clin Pathol 2006;59:56-63 (Pubitemid 43076239)
58. Holen I, Shipman CM. Role of osteoprotegerin (OPG) in cancer. Clin Sci (Lond) 2006;110:279-291 (Pubitemid 43348393)
59. Canon JR, Roudier M, Bryant R, et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 2008;25:119-129
60. Chen G, Sircar K, Aprikian A, et al. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006;107:289-298 (Pubitemid 44036558)
61. Roodman GD, Dougall WC. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 2008;34:92-101 (Pubitemid 351181016)
62. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999;140:3552-3561. (Pubitemid 30645409)
63. Futakuchi M, Nannuru KC, Varney ML, et al. Transforming growth factor-β signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation. Cancer Sci 2009;100:71-81
64. Lipton A, Jun S. RANKL inhibition in the treatment of bone metastases. Curr Opin Support Palliat Care 2008;2:197-203
65. Armstrong AP, Miller RE, Jones JC, et al. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 2008;68:92-104
66. Mountzios G, Dimopoulos MA, Bamias A, et al. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol 2007;(46):221-229 (Pubitemid 46272625)
67. Jung K, Lein M, Stephan C, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004;111:783-791 (Pubitemid 39062904)
68. Eaton CL, Wells JM, Holen I, et al. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate 2004;59:304-310 (Pubitemid 38509763)
69. Leeming DJ, Koizumi M, Byrjalsen I, et al. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 2006;15:32-38
70. Mizutani Y, Matsubara H, Yamamoto K, et al. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma. Cancer 2004;101:1794-1802 (Pubitemid 39314742)
71. Lipton A, Ali SM, Leitzel K, et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 2002;8:2306-2310 (Pubitemid 34753605)
72. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-1244 • A basic paper on the role of OPG in osteoclastogenesis and bone metastases in prostate cancer. (Pubitemid 32494540)
73. Zhang J, Dai J, Yao Z, et al. Soluble receptor activator of nuclear factor κB Fc diminishes prostate cancer progression in bone. Cancer Res 2003;63:7883-7890 (Pubitemid 37466723)
74. Yonou H, Kanomata N, Goya M, et al. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res 2003;63:2096-2102 (Pubitemid 36538612)
75. Kiefer JA, Vessella RL, Quinn JE, et al. The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clin Exp Metastasis 2004;21:381-387
76. Miller RE, Roudier M, Jones J, et al. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther 2008;7:2160-2169
77. Ignatoski KM, Escara-Wilke JF, Dai JL, et al. RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model. Prostate 2008;68:820-829 (Pubitemid 351845213)
78. Virk MS, Petrigliano FA, Liu NQ, et al. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone. Bone 2009;44:160-167
79. Feeley BT, Liu NQ, Conduah AH, et al. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:fc administration. J Bone Miner Res 2006;21:1571-1580 (Pubitemid 44484602)
80. Yaccoby S, Pearse RN, Johnson CL, et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002;116:278-290 (Pubitemid 34156975)
81. Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001;98:3534-3540
82. Vanderkerken K, De Leenheer E, Shipman C, et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003;63:287-289 (Pubitemid 36152481)
83. Heath DJ, Vanderkerken K, Cheng X, et al. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res 2007;67:202-208 (Pubitemid 46142776)
84. Morony S, Warmington K, Adamu S, et al. The RANKL inhibitor osteoprotegerin (OPG) causes greater suppression of bone resorption and hypercalcemia compared to bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 2005;146:3235-3243 (Pubitemid 41058092)
85. Roudier MP, Bain SD, Dougall WC. Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats. Clin Exp Metastasis 2006;23:167-175 (Pubitemid 44673806)
86. Lamoureux F, Richard P, Wittrant Y, et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res 2007;67:7308-7318 (Pubitemid 47206560)
87. Granchi D, Amato I, Battistelli L, et al. In vitro blockade of receptor activator of nuclear factor-κB ligand prevents osteoclastogenesis induced by neuroblastoma cells. Int J Cancer 2004;111:829-838
88. Body JJ, Greipp P, Coleman RE, et al. A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003;97:887-892 (Pubitemid 36125828)
89. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008;113:193-201 (Pubitemid 351976401)
90. Coleman R, Brown J, Terpos E, et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 2008;34:629-639
91. Kostenuik P, Nguyen H, McCabe J, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases bone density in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009;24:182-195
92. Hamdy NA. Denosumab: RANKL inhibition in the management of bone loss. Drugs Today (Barc) 2008;44:7-21
93. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-1228 (Pubitemid 43342512)
94. Yonemori K, Fujiwara Y, Minami H, et al. Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases. Cancer Sci 2008;99:1237-1242 (Pubitemid 351676637)
95. Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled Phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25:4431-4437 •• The first randomized trial, to our knowledge, of denosumab in breast cancer patients. (Pubitemid 350013849)
96. Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008;14:6690-6696
97. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875-4882
98. Fizazi K, Lipton A, Mariette X, et al. Denosumab in patients with bone metastases from prostate, breast, and other cancers and elevated urinary N-telopeptide (uNTx) during intravenous bisphosphonate (IV BP) therapy: final results of a randomized, Phase II study [abstract 3596]. J Clin Oncol 2008;26(Suppl)
99. Vij R, Horvath N, Spencer A, et al. An open-label, Phase 2 trial of denosumab in the treatment of relapsed (R) or plateau-phase (PP) multiple myeloma (MM) [abstract 3604]. Blood 2007;110(Suppl 1):1054A
100. Terpos E, Christoulas D, Dimopoulos MA. Antibodies to receptor activator of nuclear factor-κB ligand (RANKL). Expert Opin Ther Patents 2008;18:1265-1269
101. Tanaka S. A novel therapeutic vaccine approach against RANKL that prevents pathological bone destruction. Clin Calcium 2005;15:62-66